Antibiotic resistance forecasting for clinicians
Raised to date
$713K
of $2M offered across 1 Form D filing
Informuta builds software that forecasts whether an infection will become resistant to treatment. It maps whole-genome mutational signatures with models trained on longitudinal datasets, so clinicians can choose therapies less likely to fail. A peer-reviewed proof-of-concept study appeared in Nature Communications, and prospective clinical studies are underway. The company was co-founded in 2023 by Kalen Hall and Leo Williams, both Tulane PhD alumni.
Predicts resistance that emerges during treatment, not only resistance already present, using explainable genomic models.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Nov 5, 2026 | Debt | $713K/ $2M | Form D |
Clinical decision support
Forecasts treatment-emergent antimicrobial resistance risk from whole-genome mutational signatures.
Built for
Clinical microbiology labs, infectious disease pharmacists and antimicrobial stewardship programs